Carmubris en es it fr

Carmubris Brand names, Carmubris Analogs

Carmubris Brand Names Mixture

  • No information avaliable

Carmubris Chemical_Formula


Carmubris RX_link

Carmubris fda sheet

Carmubris msds (material safety sheet)

Carmubris MSDS

Carmubris Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Carmubris Molecular Weight

214.049 g/mol

Carmubris Melting Point

31 oC

Carmubris H2O Solubility

< 0.1 g/100 mL at 18 °C

Carmubris State


Carmubris LogP


Carmubris Dosage Forms

Powder for solution; Wafer

Carmubris Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Carmubris Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Carmubris Absorption

5 to 28% bioavailability

Carmubris side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Carmubris Patient Information

No information avaliable

Carmubris Organisms Affected

Humans and other mammals